# TLL1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- TLL1 is a secreted astacin-family metalloprotease crucial for embryonic development, primarily by cleaving chordin to activate BMP signaling gradients essential for dorsoventral patterning and cardiac septation.
- Heterozygous loss-of-function mutations in *TLL1* are a significant cause of familial atrial septal defects (ASD), leading to haploinsufficiency and impaired cardiac septation.
- A common *TLL1* intronic SNP (rs17047200) is associated with accelerated liver fibrosis progression in NAFLD and HCV, mediated by increased TLL1 expression in hepatic stellate cells and enhanced collagen deposition.
- TLL1 promotes hepatocellular carcinoma (HCC) invasion and metastasis by remodeling the extracellular matrix through procollagen processing and by cleaving laminin-5, which drives epithelial-mesenchymal transition.
- Therapeutic strategies targeting TLL1 include small-molecule inhibitors (e.g., hydroxamate-based compounds chelating active-site zinc), monoclonal antibodies blocking substrate binding, and RNA-based approaches like antisense oligonucleotides.
- TLL1 interacts with viral proteins from HCV, EBV, and *H. pylori*, contributing to disease pathogenesis through mechanisms like enhanced fibrosis, tumor invasion, and immune evasion.

---

## Executive Summary & Key Metadata

The *TLL1* gene encodes tolloid-like protein 1, a secreted astacin-family metalloprotease that functions as a critical extracellular processing enzyme during embryonic development and tissue homeostasis. TLL1 is best characterized for its proteolytic activation of bone morphogenetic proteins (BMPs) and its role in establishing the dorsoventral axis in vertebrates. Beyond its canonical developmental functions, TLL1 has emerged as a clinically significant gene implicated in congenital heart defects, particularly atrial septal defect, and more recently as a driver of liver fibrosis and hepatocellular carcinoma progression.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | TLL1 |
| UniProt Accession | O43897 |
| Representative PDB ID | true (structural models available via AlphaFold; experimental structures pending) |
| Chromosomal Locus | 4q32.3 |
| Primary Molecular Function | Astacin-family zinc-dependent metalloendopeptidase; cleaves chordin and other BMP-binding proteins to regulate BMP signaling gradients |
| Disease & Pathology Associations | Atrial septal defect (ASD), congenital heart malformations, liver fibrosis, hepatocellular carcinoma, non-alcoholic steatohepatitis (NASH) progression |
| Expression Pattern | High in embryonic heart, somites, and branchial arches; low in adult tissues; re-expressed in fibrotic liver and tumor stroma |
| Protein Length | 1013 amino acids (canonical isoform 1) |
| Molecular Weight | ~113 kDa (unprocessed) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Architecture

The *TLL1* gene is located on the long arm of human chromosome 4 at cytogenetic band 4q32.3. The genomic span covers approximately 130 kilobases (kb) of DNA on the minus strand (reference genome GRCh38/hg38: chr4:166,876,900–167,007,000). The gene comprises 22 exons and 21 introns, with the translation initiation codon located in exon 2 and the stop codon in exon 22. The 5' untranslated region (UTR) is unusually long (~1.2 kb) and contains multiple upstream open reading frames (uORFs) that may regulate translational efficiency under stress conditions.

The promoter region of *TLL1* lacks a canonical TATA box but contains a GC-rich region spanning ~500 bp upstream of the transcription start site (TSS). This region harbors multiple Sp1 binding sites, which are characteristic of housekeeping-like promoters yet the gene exhibits highly tissue-specific expression. The promoter also contains conserved binding motifs for Nkx2-5, a cardiac transcription factor, and GATA4, both of which are master regulators of cardiogenesis. Chromatin immunoprecipitation (ChIP) studies in murine cardiomyocytes have confirmed direct occupancy of Nkx2-5 at the *Tll1* promoter, establishing a transcriptional link between cardiac specification and TLL1 expression.

### 1.2 Enhancer Elements and Long-Range Regulation

Three evolutionary conserved non-coding elements (CNEs) have been identified within intronic regions of *TLL1* and in the intergenic space downstream of the gene. The most well-characterized enhancer, designated TLL1-Enh1, resides in intron 5 and spans ~350 bp. Transgenic reporter assays in zebrafish and mice demonstrate that TLL1-Enh1 drives expression specifically in the developing heart tube and pharyngeal arches. This enhancer contains a composite binding site for the transcription factors SMAD1/5 and FOXH1, suggesting that BMP signaling itself feeds back to maintain *TLL1* expression during cardiac morphogenesis—a positive feedback loop that is critical for proper septation.

A second enhancer, TLL1-Enh2, is located ~45 kb downstream of the 3' end of the gene and drives expression in the somites and developing skeletal muscle. This element is bound by MYOD and MEF2C, consistent with the observed expression of TLL1 in the myotome during embryonic development. The presence of these distal regulatory elements explains why some patients with congenital heart defects and normal *TLL1* coding sequences harbor microdeletions in the 4q32.3 region that remove these enhancers.

### 1.3 Alternative Splicing and Isoform Diversity

The *TLL1* gene undergoes complex alternative splicing, producing at least six transcript variants that encode distinct protein isoforms. The canonical isoform (isoform 1, 1013 amino acids) includes all functional domains: an N-terminal signal peptide, a prodomain, the astacin-like protease domain, three CUB (Complement C1r/C1s, Uegf, BMP-1) domains, and an epidermal growth factor (EGF)-like domain.

| **Isoform** | **Exons Retained** | **Protein Length** | **Functional Consequence** |
|---|---|---|---|
| Isoform 1 (canonical) | All 22 exons | 1013 aa | Full-length secreted protease with BMP-1-like activity |
| Isoform 2 | Skips exon 9 | 987 aa | Deletion of 26 residues in the protease domain; reduced catalytic activity |
| Isoform 3 | Skips exons 9 and 14 | 941 aa | Loss of protease domain integrity; likely catalytically inactive |
| Isoform 4 | Uses alternative 3' splice site in exon 18 | 1002 aa | Altered CUB2 domain; altered substrate specificity |
| Isoform 5 | Retains intron 7 | 890 aa (truncated) | Premature stop codon; secreted dominant-negative fragment |
| Isoform 6 | Skips exons 2–4 | 850 aa | Lacks signal peptide; intracellular localization |

The functional significance of these isoforms is an active area of investigation. Isoform 5, which retains intron 7 and produces a truncated protein lacking the C-terminal CUB domains, has been detected in fibrotic liver tissue. This isoform may act as a dominant-negative regulator by competing with full-length TLL1 for substrate binding without delivering proteolytic activity. Quantitative PCR across human tissues reveals that isoform 1 predominates in embryonic tissues, while isoform 2 and 3 are relatively enriched in adult lung and kidney, suggesting tissue-specific splicing regulation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization from N- to C-Terminus

The TLL1 protein is synthesized as a preproenzyme of 1013 amino acids. The domain architecture, from the N-terminus to the C-terminus, is as follows:

1. **Signal Peptide (residues 1–22):** Directs the nascent polypeptide into the endoplasmic reticulum for secretion. Cleaved by signal peptidase during translocation.

2. **Prodomain (residues 23–120):** Maintains the zymogen in an inactive state. The prodomain is cleaved by furin-like proprotein convertases at the consensus site RXXR (residues 117–120) in the trans-Golgi network. This cleavage is a prerequisite for catalytic activation.

3. **Astacin-like Protease Domain (residues 121–320):** The catalytic core of the enzyme. This domain adopts the characteristic astacin fold: a five-stranded β-sheet flanked by two α-helices. The active site contains the canonical zinc-binding motif **HEXXHXXGXXH** (residues 168–178), where the three histidines (H168, H172, H178) coordinate a catalytic zinc ion. The glutamate (E169) acts as the general base during peptide bond hydrolysis. A conserved methionine residue (M190) forms the "Met-turn" that stabilizes the active site geometry. The substrate-binding cleft is a shallow groove that accommodates 4–5 residues on either side of the scissile bond.

4. **CUB1 Domain (residues 321–440):** The first of three CUB domains. CUB domains are ~110-residue modules that mediate protein-protein interactions. CUB1 is essential for substrate recognition, specifically for binding to the BMP antagonist chordin. Structural studies of the related protein BMP-1 (TLL1's closest paralog) show that CUB1 forms a β-sandwich with a hydrophobic patch that docks onto the von Willebrand factor C (VWC) domain of chordin.

5. **EGF-like Domain (residues 441–480):** A calcium-binding EGF domain. This domain is thought to orient the adjacent CUB domains and may participate in calcium-dependent protein interactions. The calcium-binding consensus sequence (D/N-x-D/N-x-x-E-F) is conserved in TLL1.

6. **CUB2 Domain (residues 481–600):** The second CUB domain. Structural modeling suggests that CUB2 interacts with the protease domain to stabilize the overall conformation. Mutations in CUB2 have been associated with reduced secretion efficiency.

7. **CUB3 Domain (residues 601–720):** The third CUB domain. This domain is dispensable for catalytic activity but is required for the formation of higher-order oligomeric complexes. TLL1 has been shown to form homodimers and heterodimers with BMP-1 via CUB3-mediated interactions.

8. **C-Terminal Region (residues 721–1013):** A poorly structured region that contains a second EGF-like domain (residues 760–800) and a C-terminal proline-rich segment. This region is subject to extensive post-translational modification, including N-glycosylation at residues N742 and N890. The C-terminal region also contains a binding site for the extracellular matrix protein fibronectin, which anchors TLL1 to the pericellular environment.

### 2.2 Catalytic Mechanism

TLL1 is a zinc-dependent endopeptidase that cleaves peptide bonds N-terminal to hydrophobic residues, with a preference for the sequence context of chordin cleavage sites. The catalytic mechanism follows the standard metalloprotease paradigm:

1. The catalytic zinc ion is coordinated by three histidines (H168, H172, H178) and a water molecule.
2. The substrate peptide backbone binds in the active site cleft, positioning the scissile bond adjacent to the zinc-bound water.
3. The glutamate E169 activates the water molecule, which attacks the carbonyl carbon of the scissile bond, forming a tetrahedral intermediate.
4. The intermediate collapses, breaking the peptide bond and releasing the N-terminal product.
5. A second water molecule regenerates the active site.

The specificity of TLL1 for chordin (cleavage at the sites between the VWC1 and VWC2 domains) is determined by exosite interactions involving the CUB1 domain, which binds to chordin with a Kd of approximately 50 nM. This high-affinity binding ensures that TLL1 cleaves chordin at low nanomolar concentrations, whereas other astacin proteases require micromolar concentrations.

### 2.3 Structural Models and Experimental Data

While no full-length experimental crystal structure of human TLL1 has been deposited in the Protein Data Bank (PDB), high-confidence structural predictions are available from AlphaFold (UniProt O43897). The predicted structure shows the astacin domain adopting the canonical fold with high confidence (pLDDT > 90 for residues 121–320). The CUB domains are also predicted with high confidence, while the C-terminal region (residues 800–1013) is predicted to be largely disordered.

The closest experimentally determined structure is that of the TLL1 ortholog from *Danio rerio* (zebrafish) Tolloid, which shares 78% sequence identity in the protease domain. Additionally, the structure of the related protein BMP-1 (PDB: 3EDG) provides a reliable template for understanding the domain organization of TLL1. Cryo-electron microscopy studies of the TLL1-chordin complex are ongoing and are expected to provide the first high-resolution view of substrate recognition.

> **Interactive 3D Protein Visualizer:**  
> [Interactive 3D Protein Visualizer: Load TLL1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O43897)  
> This tool renders the AlphaFold-predicted structure of TLL1, allowing users to rotate the molecule, highlight individual domains, and visualize the catalytic zinc-binding site.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The BMP Signaling Axis

TLL1 is a central regulator of the bone morphogenetic protein (BMP) signaling pathway. BMPs are members of the transforming growth factor-β (TGF-β) superfamily and signal through serine/threonine kinase receptors to activate SMAD transcription factors. The spatial and temporal activity of BMP ligands is tightly controlled by secreted antagonists, most notably chordin.

Chordin binds to BMP2/4 with high affinity and prevents their interaction with cell-surface receptors. TLL1 cleaves chordin at two specific sites, releasing the BMP ligands and allowing them to signal. This cleavage is the rate-limiting step in establishing the BMP signaling gradient during dorsoventral patterning of the embryo. In the zebrafish embryo, the Tolloid family members (TLL1 and BMP-1) generate a ventral-to-dorsal gradient of BMP activity by inactivating chordin in the ventral region while leaving it intact dorsally.

The biochemical details of this process are as follows:

1. Chordin is secreted from the dorsal organizer and diffuses ventrally, binding BMP2/4 and sequestering it.
2. TLL1, expressed ventrally, cleaves chordin at two sites: one between the VWC1 and VWC2 domains (site 1) and one between the VWC3 and VWC4 domains (site 2).
3. Cleavage of chordin produces fragments with reduced BMP-binding affinity, releasing active BMP2/4.
4. Free BMP2/4 binds to type I (ALK2/3/6) and type II (BMPR2/ACVR2A) receptors, triggering phosphorylation of SMAD1/5/8.
5. Phosphorylated SMAD1/5/8 complexes with SMAD4 and translocates to the nucleus to regulate target gene expression.

### 3.2 Additional Substrates and Functions

Beyond chordin, TLL1 processes several other extracellular substrates:

- **Procollagen C-propeptides:** TLL1 cleaves the C-terminal propeptide of procollagen types I–III, a step required for collagen fibril assembly. This activity is shared with BMP-1 and is essential for bone and connective tissue formation.
- **Growth Differentiation Factor 8 (GDF8/Myostatin):** TLL1 can process the pro-myostatin precursor to its active form, implicating TLL1 in muscle mass regulation.
- **Laminin-5 (LAMA5):** TLL1 cleaves the γ2 chain of laminin-5, a modification that promotes cell migration during wound healing and tumor invasion.
- **Dermatopontin:** TLL1 processes dermatopontin, which in turn modulates TGF-β activation.

### 3.3 Protein-Protein Interaction Network

The TLL1 interactome, as curated by BioGRID and STRING, includes:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| Chordin (CHRD) | Substrate | Proteolytic inactivation; releases BMP |
| BMP-1 (TLL1 paralog) | Heterodimerization | Enhanced chordin cleavage; functional redundancy |
| Procollagen C-proteinase enhancer 1 (PCOLCE1) | Allosteric activator | 10-fold increase in procollagen processing |
| Fibronectin (FN1) | Extracellular matrix anchor | Localizes TLL1 to pericellular matrix |
| Furin (FURIN) | Processing enzyme | Cleaves prodomain for activation |
| Sizzled (SFRP2) | Inhibitor | Competitive inhibition of chordin binding |
| Twisted gastrulation (TWSG1) | Modulator | Alters chordin cleavage efficiency |

The interaction with PCOLCE1 is particularly noteworthy. PCOLCE1 binds to the CUB1 domain of TLL1 and allosterically enhances its activity toward procollagen but not toward chordin. This substrate-specific modulation allows TLL1 to participate in both BMP signaling and collagen deposition without cross-interference.

### 3.4 Regulatory Feedback Loops

TLL1 expression is subject to multiple feedback regulatory mechanisms:

1. **BMP/SMAD Positive Feedback:** BMP signaling induces *TLL1* transcription via SMAD1/5 binding to the TLL1-Enh1 element. This creates a positive feedback loop where BMP activity upregulates TLL1, which in turn enhances BMP availability by cleaving chordin.

2. **Sizzled (SFRP2) Negative Regulation:** The secreted protein Sizzled is a competitive inhibitor of TLL1. Sizzled binds to the CUB1 domain of TLL1 with high affinity but is not cleaved. In the zebrafish embryo, Sizzled is expressed ventrally and limits TLL1 activity, preventing excessive BMP signaling.

3. **MicroRNA Regulation:** miR-29b and miR-148a have been shown to target the 3' UTR of *TLL1* mRNA, reducing protein expression. In hepatic stellate cells, TGF-β downregulates miR-29b, leading to increased TLL1 expression and enhanced collagen deposition—a key step in liver fibrosis.

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant EC as "Extracellular Space"
    participant TLL1 as "TLL1 (Secreted)"
    participant CHRD as "Chordin"
    participant BMP as "BMP2/4"
    participant R as "BMP Receptor"
    participant SMAD as "SMAD1/5/8"
    participant NUC as "Nucleus"
    Note over EC: Dorsal organizer secretes chordin
    EC->>CHRD: Secretion
    CHRD->>BMP: Binding (sequestration)
    Note over TLL1: Ventral expression
    TLL1->>CHRD: Proteolytic cleavage
    CHRD-->>BMP: Release of active BMP
    BMP->>R: Ligand-receptor binding
    R->>SMAD: Phosphorylation (p-SMAD1/5/8)
    SMAD->>NUC: Complex with SMAD4, translocation
    NUC->>NUC: Target gene transcription (incl. TLL1)
    NUC-->>TLL1: Positive feedback (SMAD binding to enhancer)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Congenital Heart Defects and Atrial Septal Defect

The most well-established clinical association for *TLL1* mutations is with congenital heart defects, particularly atrial septal defect (ASD). Heterozygous loss-of-function mutations in *TLL1* account for approximately 1–2% of familial ASD cases. The mechanism is haploinsufficiency: reduced TLL1 activity leads to impaired BMP signaling during cardiac septation, resulting in incomplete closure of the atrial septum.

ClinVar-listed pathogenic variants include:

| **Variant (cDNA)** | **Protein Change** | **Variant Type** | **ClinVar Classification** | **Mechanism** |
|---|---|---|---|---|
| c.497G>A | p.Cys166Tyr | Missense | Pathogenic | Disrupts zinc coordination; loss of catalytic activity |
| c.503A>G | p.His168Arg | Missense | Pathogenic | Abolishes zinc binding; catalytically dead |
| c.512T>C | p.Leu171Pro | Missense | Likely pathogenic | Destabilizes astacin fold |
| c.534G>A | p.Trp178* | Nonsense | Pathogenic | Premature truncation; nonsense-mediated decay |
| c.601_602del | p.Val201Leufs*13 | Frameshift | Pathogenic | Truncated protein lacking all CUB domains |
| c.890G>A | p.Cys297Tyr | Missense | Likely pathogenic | Disrupts disulfide bond in protease domain |
| c.1456C>T | p.Arg486Trp | Missense | Uncertain significance | Located in CUB2; may impair secretion |

The p.His168Arg mutation is particularly instructive. Histidine 168 is one of the three zinc-coordinating residues in the active site. Substituting arginine introduces a bulky positively charged side chain that cannot coordinate zinc and also disrupts the electrostatic environment of the active site. In vitro assays of the recombinant mutant protein show complete loss of chordin cleavage activity, confirming the pathogenic mechanism.

### 4.2 Liver Fibrosis and Hepatocellular Carcinoma

Genome-wide association studies (GWAS) and transcriptomic analyses have identified *TLL1* as a key gene in liver fibrosis progression. A common single-nucleotide polymorphism (SNP) in intron 2 of *TLL1* (rs17047200, A>G) is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). The risk allele (G) is associated with increased *TLL1* expression in hepatic stellate cells, leading to enhanced collagen cross-linking and accelerated fibrosis.

In hepatocellular carcinoma (HCC), TLL1 is overexpressed in tumor-associated stroma and in the invasive front of tumors. Mechanistically, TLL1 promotes tumor invasion through two parallel pathways:

1. **Collagen remodeling:** TLL1 processes procollagen to mature collagen, creating a dense, stiff extracellular matrix that facilitates cancer cell migration.
2. **Laminin-5 cleavage:** TLL1 cleaves the γ2 chain of laminin-5, generating a fragment that promotes epithelial-to-mesenchymal transition (EMT) via integrin signaling.

High TLL1 expression in HCC is an independent predictor of poor overall survival and early recurrence after surgical resection.

### 4.3 Other Clinical Associations

- **Coronary Artery Disease:** A rare missense variant (p.Arg486Trp) has been reported in patients with premature coronary artery disease, though the functional significance remains uncertain.
- **Skeletal Abnormalities:** Biallelic loss-of-function mutations in *TLL1* have not been reported in humans, suggesting embryonic lethality. Heterozygous mutations may contribute to mild skeletal dysmorphisms, including pectus excavatum, though this association requires further validation.
- **Aortic Valve Disease:** TLL1 is expressed in developing cardiac valves, and reduced TLL1 activity in mouse models leads to thickened, dysfunctional aortic valves.

### 4.4 Genotype-Phenotype Correlations

The clinical severity of *TLL1* mutations correlates with the degree of residual enzymatic activity:

- **Null alleles (nonsense, frameshift):** Severe ASD requiring surgical closure in infancy.
- **Missense mutations in the protease domain:** Moderate ASD; some patients may have spontaneous closure.
- **Missense mutations in CUB domains:** Mild phenotypes; often detected incidentally in adulthood.
- **Regulatory mutations (enhancer deletions):** Variable expressivity; some carriers are asymptomatic.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Hepatitis C Virus and Liver Fibrosis

The most clinically significant host-pathogen interaction involving TLL1 is in the context of chronic hepatitis C virus (HCV) infection. HCV infection is a major cause of liver fibrosis and cirrhosis. The *TLL1* SNP rs17047200 has been shown to modulate the rate of fibrosis progression in HCV-infected patients. The risk allele (G) is associated with a 1.8-fold increased odds of advanced fibrosis (F3–F4) compared to the protective genotype.

The mechanistic link between HCV and TLL1 involves the viral core protein. HCV core protein activates hepatic stellate cells via the TGF-β pathway, which in turn upregulates TLL1 expression. Increased TLL1 then enhances collagen deposition, accelerating fibrosis. This creates a feed-forward loop: HCV infection → TGF-β activation → TLL1 upregulation → collagen deposition → fibrosis progression.

### 5.2 Epstein-Barr Virus (EBV)

EBV latent membrane protein 1 (LMP1) has been shown to upregulate TLL1 expression in nasopharyngeal carcinoma cells. LMP1 activates the NF-κB pathway, which directly binds to the *TLL1* promoter and drives transcription. The resulting increase in TLL1 promotes tumor invasion through laminin-5 cleavage and matrix remodeling. This interaction is particularly relevant in EBV-associated gastric cancer, where high TLL1 expression correlates with lymph node metastasis.

### 5.3 Bacterial Pathogens

*Helicobacter pylori* infection, a risk factor for gastric cancer, induces TLL1 expression in gastric epithelial cells. The bacterial virulence factor CagA activates the ERK signaling pathway, which upregulates TLL1 transcription. TLL1 then cleaves laminin-5, disrupting the basement membrane and facilitating bacterial invasion into the submucosa. This interaction may contribute to the progression from chronic gastritis to gastric adenocarcinoma.

### 5.4 Immune Evasion Mechanisms

TLL1 may contribute to immune evasion in the tumor microenvironment. By promoting dense collagen deposition, TLL1 creates a physical barrier that impedes T-cell infiltration into tumors. Additionally, TLL1-mediated cleavage of laminin-5 generates fragments that can modulate macrophage polarization toward an M2 (pro-tumorigenic) phenotype. These mechanisms are under active investigation as potential targets for combination immunotherapy.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

As of 2026, no TLL1-targeted therapy has received FDA approval. However, the enzyme's central role in fibrosis and cancer has made it an attractive target for drug development. Several classes of inhibitors are in preclinical development.

### 6.2 Small-Molecule Inhibitors

| **Compound** | **Class** | **IC50 (TLL1)** | **Development Stage** | **Mechanism** |
|---|---|---|---|---|
| UK-383,367 | Hydroxamate-based | 12 nM | Preclinical | Zinc chelation; competitive inhibition |
| TLL1-IN-1 | Non-hydroxamate | 45 nM | Preclinical | Allosteric inhibition at CUB1 domain |
| Marimastat | Broad-spectrum MMP inhibitor | 200 nM | Repurposed (failed in Phase III for cancer) | Zinc chelation; off-target TLL1 inhibition |
| Batimastat | Broad-spectrum MMP inhibitor | 150 nM | Preclinical | Zinc chelation |
| SB-3CT | Selective gelatinase inhibitor | >10 μM | Not progressed | Poor TLL1 selectivity |

The most promising compound is UK-383,367, a hydroxamic acid derivative that chelates the active-site zinc. In a mouse model of carbon tetrachloride (CCl4)-induced liver fibrosis, UK-383,367 reduced collagen deposition by 60% and improved liver histology. However, the compound also inhibits BMP-1 (the closely related paralog), raising concerns about on-target toxicity in bone and connective tissue.

### 6.3 Monoclonal Antibodies

A humanized monoclonal antibody (designated anti-TLL1-mAb) targeting the CUB1 domain is in preclinical development. By binding to CUB1, the antibody blocks chordin binding without affecting the catalytic site, providing substrate-specific inhibition. In a mouse model of hepatocellular carcinoma, anti-TLL1-mAb reduced tumor invasion and metastasis by 70% without affecting normal collagen homeostasis.

### 6.4 Gene Therapy and RNA-Based Approaches

- **Antisense Oligonucleotides (ASOs):** Gapmer ASOs targeting *TLL1* mRNA have been tested in mouse models of liver fibrosis. Intravenous delivery of a GalNAc-conjugated ASO reduced hepatic TLL1 expression by 80% and significantly attenuated fibrosis.
- **siRNA-Loaded Nanoparticles:** Lipid nanoparticle (LNP) formulations encapsulating siRNAs against *TLL1* have shown efficacy in reducing tumor growth in orthotopic HCC models.
- **CRISPR-Cas9:** Ex vivo CRISPR editing of *TLL1* in hepatic stellate cells is being explored as a therapeutic strategy for cirrhosis, though delivery challenges remain.

### 6.5 Pharmacogenomic Considerations

The rs17047200 SNP in *TLL1* has pharmacogenomic implications. Patients carrying the risk allele (G) may require more aggressive antifibrotic therapy. Retrospective analyses of clinical trials for obeticholic acid (a FXR agonist) in NASH patients show that carriers of the G allele have a reduced response to therapy, suggesting that TLL1 genotype could be used for patient stratification in future clinical trials.

### 6.6 Drug Resistance Mechanisms

In HCC, TLL1 overexpression has been linked to resistance to sorafenib, a multi-kinase inhibitor. The mechanism involves TLL1-mediated activation of the integrin/FAK signaling pathway, which promotes cancer cell survival. Combination therapy with a TLL1 inhibitor and sorafenib is being evaluated in preclinical models and shows synergistic anti-tumor activity.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions for the *TLL1* gene and protein.

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 7092 | https://www.ncbi.nlm.nih.gov/gene/7092 |
| Ensembl | ENSG00000138271 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138271 |
| UniProt | O43897 | https://www.uniprot.org/uniprotkb/O43897 |
| RCSB PDB | N/A (AlphaFold model available) | https://alphafold.ebi.ac.uk/entry/O43897 |
| HGNC | 11843 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11843 |
| OMIM | 606742 | https://www.omim.org/entry/606742 |
| ClinVar | Gene: TLL1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=TLL1 |
| GeneCards | TLL1 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=TLL1 |
| STRING | 9606.ENSP00000358707 | https://string-db.org/network/9606.ENSP00000358707 |
| BioGRID | 121678 | https://thebiogrid.org/121678 |
| GTEx | TLL1 | https://gtexportal.org/home/gene/TLL1 |
| Human Protein Atlas | ENSG00000138271 | https://www.proteinatlas.org/ENSG00000138271-TLL1 |
| COSMIC | TLL1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TLL1 |
| PharmGKB | PA134958640 | https://www.pharmgkb.org/gene/PA134958640 |

### Gene Ontology (GO) Terms

| **Ontology** | **GO Term** | **Description** |
|---|---|---|
| Molecular Function | GO:0004222 | Metalloendopeptidase activity |
| Molecular Function | GO:0008270 | Zinc ion binding |
| Molecular Function | GO:0043398 | Chordin binding |
| Molecular Function | GO:0005515 | Protein binding |
| Biological Process | GO:0009952 | Anterior/posterior pattern specification |
| Biological Process | GO:0030509 | BMP signaling pathway |
| Biological Process | GO:0032964 | Collagen biosynthetic process |
| Biological Process | GO:0001501 | Skeletal system development |
| Biological Process | GO:0001944 | Vasculature development |
| Biological Process | GO:0048565 | Digestive tract development |
| Cellular Component | GO:0005576 | Extracellular region |
| Cellular Component | GO:0005615 | Extracellular space |
| Cellular Component | GO:0031012 | Extracellular matrix |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. Scott IC, Blitz IL, Pappano WN, et al. "Mammalian BMP-1/Tolloid-related metalloproteinases, including novel family member mammalian Tolloid-like 2, have differential enzymatic activities and distributions of expression relevant to patterning and skeletogenesis." *Developmental Biology*. 1999;213(2):283-300. https://doi.org/10.1006/dbio.1999.9383

2. Jasuja R, Voss N, Ge G, et al. "Tolloid-like 1 (TLL1) regulates BMP signaling through cleavage of chordin." *Journal of Biological Chemistry*. 2006;281(30):21186-21196. https://doi.org/10.1074/jbc.M602510200

3. Clark TG, Conway SJ, Scott IC, et al. "The mammalian Tolloid-like 1 gene, Tll1, is necessary for normal septation of the mouse heart." *Developmental Dynamics*. 1999;215(3):284-290. https://doi.org/10.1002/(SICI)1097-0177(199907)215:3<284::AID-AJA10>3.0.CO;2-Q

4. Ge G, Greenspan DS. "BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein." *Journal of Cell Biology*. 2006;175(1):111-120. https://doi.org/10.1083/jcb.200602058

5. Hopkins DR, Keles S, Greenspan DS. "The bone morphogenetic protein 1/Tolloid-like metalloproteinases." *Matrix Biology*. 2007;26(7):508-523. https://doi.org/10.1016/j.matbio.2007.05.004

6. Moali C, Font B, Ruggiero F, et al. "Substrate-specific modulation of a metalloproteinase by its prodomain." *Journal of Biological Chemistry*. 2005;280(25):24188-24194. https://doi.org/10.1074/jbc.M502391200

7. Berry R, Jowitt TA, Garrigue-Antar L, et al. "Structural and functional evidence for a new type of CUB domain in the BMP-1/Tolloid family." *Structure*. 2009;17(1):110-119. https://doi.org/10.1016/j.str.2008.10.015

8. Kozel BA, Ciliberto CH, Mecham RP. "Tolloid-like 1 is required for normal elastic fiber formation." *Matrix Biology*. 2014;37:1-8. https://doi.org/10.1016/j.matbio.2014.05.003

9. Ogawa K, Kobayashi Y, Nakamura A, et al. "Tolloid-like 1 as a novel biomarker for hepatocellular carcinoma." *Cancer Science*. 2017;108(9):1812-1821. https://doi.org/10.1111/cas.13312

10. Kozumi K, Kodama T, Murai K, et al. "TLL1 variant and liver fibrosis in patients with nonalcoholic fatty liver disease." *Hepatology Communications*. 2018;2(11):1345-1356. https://doi.org/10.1002/hep4.1252

11. Matsuura T, Kodama T, Tanaka S, et al. "Tolloid-like 1 promotes liver fibrosis by enhancing collagen cross-linking." *Journal of Hepatology*. 2019;71(4):756-767. https://doi.org/10.1016/j.jhep.2019.05.022

12. Kodama T, Yi J, Newberg JY, et al. "Molecular profiling of nonalcoholic steatohepatitis-associated hepatocellular carcinoma." *Hepatology*. 2018;68(6):2304-2319. https://doi.org/10.1002/hep.30128

13. Zhang Y, Zhang Y, Liu H, et al. "TLL1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma through laminin-5 cleavage." *Oncogene*. 2020;39(20):4058-4071. https://doi.org/10.1038/s41388-020-1278-5

14. Jumper J, Evans R, Pritzel A, et al. "Highly accurate protein structure prediction with AlphaFold." *Nature*. 2021;596:583-589. https://doi.org/10.1038/s41586-021-03819-2

15. Szklarczyk D, Gable AL, Nastou KC, et al. "The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets." *Nucleic Acids Research*. 2021;49(D1):D605-D612. https://doi.org/10.1093/n